Astrana Health Inc. Common Stock

ASTH

AstraHealth Inc. (ASTH) is a healthcare technology company focused on developing innovative solutions to improve patient outcomes and streamline healthcare delivery. The company specializes in digital health platforms, data analytics, and telemedicine services designed to enhance clinical decision-making and support healthcare providers.

$44.94 -0.16 (-0.35%)
🚫 Astrana Health Inc. Common Stock does not pay dividends

Company News

UnitedHealth, Humana, CVS Jump As CMS Boosts Medicare Payments
Benzinga • Vandana Singh • April 7, 2026

The Centers for Medicare & Medicaid Services announced a 2.48% increase in 2027 Medicare Advantage capitation rates, exceeding initial expectations of 0.09%. The boost amounts to over $13 billion in additional payments and reflects a 4.98% increase when accounting for risk score trends. CMS retained the 2024 risk adjustment model, providing great...

Astrana Health, Inc. Reports Second Quarter 2025 Results
Benzinga • Prnewswire • August 7, 2025

Astrana Health reported strong Q2 2025 financial results with total revenue of $654.8 million, up 35% year-over-year, and completed its acquisition of Prospect Health, expanding its healthcare service platform.

Here is Why Growth Investors Should Buy Astrana Health, Inc. (ASTH) Now
Zacks Investment Research • Zacks Equity Research • May 6, 2024

Astrana Health, Inc. (ASTH) possesses solid growth attributes, which could help it handily outperform the market.

DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research • Zacks Equity Research • May 2, 2024

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 21.43% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Option Care (OPCH) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research • Zacks Equity Research • April 23, 2024

Option Care (OPCH) delivered earnings and revenue surprises of 18.18% and 4.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Related Companies